EFFICACY AND SAFETY OF GIVOSIRAN IN PATIENTS WITH ACUTE HEPATIC PORPHYRIA: 24-MONTH INTERIM ANALYSIS OF THE PHASE 3 ENVISION RANDOMIZED CLINICAL TRIAL

Herbert L. Bonkovsky  1     Paolo Ventura  2     Laurent Gouya  3     Paula Aguilera Peiró  4     D. Montgomery Bissell  5     Penelope E. Stein  6     Manisha Balwani  7     D. Karl E. Anderson  8     Charles Parker  9     David J. Kuter  10     Susana Monroy  11     Jeeyoung Oh  12     Bruce Ritchie  13     Zhaowei Hua  14     Eliane Sardh  15     John Ko  14     Marianne T Sweetser  14    
1 Wake Forest University/NC Baptist Medical Center, Winston-Salem, United States
2 University of Modena and Reggio Emilia, Modena, Italy
3 Centre Français des Porphyries, Paris, France
4 Hospital Clinic Barcelona, Barcelona, Spain
5 University of California, San Francisco, United States
6 King’s College Hospital, London, United Kingdom
7 Icahn School of Medicine at Mt. Sinai, New York, United States
8 University of Texas Medical Branch, Galveston, United States
9 University of Utah, Salt Lake City, United States
10 Massachusetts General Hospital, Boston, United States
11 Instituto Nacional de Pediatría de Mexico, Mexico City, Mexico
12 Konkuk University Medical Center, Seoul, Korea, Republic of
13 University of Alberta Hospital, Edmonton, Canada
14 Alnylam Pharmaceuticals, Cambridge, United States
15 Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

Topic
Digestive Oncology, Hepatobiliary

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing